$HRMY
Harmony Biosciences Holdings Inc

2023 Q2 Form 10-Q Financial Statement

#000155837023007571 Filed on May 02, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $134.2M $119.1M
YoY Change 25.4% 39.63%
Cost Of Revenue $25.01M $20.78M
YoY Change 32.17% 41.21%
Gross Profit $109.2M $98.35M
YoY Change 23.95% 39.31%
Gross Profit Margin 81.37% 82.56%
Selling, General & Admin $47.34M $44.63M
YoY Change 11.85% 25.86%
% of Gross Profit 43.35% 45.38%
Research & Development $14.97M $13.29M
YoY Change 18.16% 75.36%
% of Gross Profit 13.71% 13.51%
Depreciation & Amortization $6.064M $103.0K
YoY Change 0.15% -11.97%
% of Gross Profit 5.55% 0.1%
Operating Expenses $62.31M $57.92M
YoY Change 13.3% 34.58%
Operating Profit $46.90M $40.42M
YoY Change 41.63% 46.69%
Interest Expense -$2.776M -$2.645M
YoY Change -29.31% -36.56%
% of Operating Profit -5.92% -6.54%
Other Income/Expense, Net -$31.00K $2.000K
YoY Change -173.81% -200.0%
Pretax Income $44.10M $37.78M
YoY Change 50.85% 61.56%
Income Tax $9.795M $8.295M
% Of Pretax Income 22.21% 21.96%
Net Earnings $34.30M $29.49M
YoY Change 45.77% 37.24%
Net Earnings / Revenue 25.56% 24.75%
Basic Earnings Per Share $0.57 $0.49
Diluted Earnings Per Share $0.56 $0.48
COMMON SHARES
Basic Shares Outstanding 59.95M 59.62M
Diluted Shares Outstanding 60.74M 61.22M

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $371.0M $343.9M
YoY Change 45.96% 53.18%
Cash & Equivalents $317.4M $288.0M
Short-Term Investments $53.57M $55.92M
Other Short-Term Assets $15.99M $6.145M
YoY Change 335.27% 80.21%
Inventory $4.854M $4.090M
Prepaid Expenses $9.442M $11.40M
Receivables $63.81M $52.58M
Other Receivables $0.00 $0.00
Total Short-Term Assets $455.6M $418.1M
YoY Change 41.2% 49.18%
LONG-TERM ASSETS
Property, Plant & Equipment $2.629M $470.0K
YoY Change 278.27% -37.17%
Goodwill
YoY Change
Intangibles $149.0M $155.0M
YoY Change -13.79% -13.33%
Long-Term Investments $58.65M $48.54M
YoY Change 1135.54%
Other Assets $94.23M $2.870M
YoY Change 2786.98% -15.91%
Total Long-Term Assets $304.5M $297.0M
YoY Change 67.03% 61.64%
TOTAL ASSETS
Total Short-Term Assets $455.6M $418.1M
Total Long-Term Assets $304.5M $297.0M
Total Assets $760.2M $715.1M
YoY Change 50.52% 54.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.563M $6.414M
YoY Change -1.47% -7.1%
Accrued Expenses $73.32M $56.81M
YoY Change 60.7% 44.26%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $11.00M $6.500M
YoY Change 450.0% 225.0%
Total Short-Term Liabilities $93.05M $85.36M
YoY Change 41.48% 51.01%
LONG-TERM LIABILITIES
Long-Term Debt $180.5M $185.1M
YoY Change -4.91% -2.55%
Other Long-Term Liabilities $1.479M $1.625M
YoY Change -49.52% -47.21%
Total Long-Term Liabilities $182.0M $186.7M
YoY Change -5.59% -3.26%
TOTAL LIABILITIES
Total Short-Term Liabilities $93.05M $85.36M
Total Long-Term Liabilities $182.0M $186.7M
Total Liabilities $275.0M $272.1M
YoY Change 6.39% 9.04%
SHAREHOLDERS EQUITY
Retained Earnings -$208.3M -$242.6M
YoY Change -49.01% -43.85%
Common Stock $694.0M $685.7M
YoY Change 5.94% 6.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $485.2M $443.0M
YoY Change
Total Liabilities & Shareholders Equity $760.2M $715.1M
YoY Change 50.52% 54.11%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income $34.30M $29.49M
YoY Change 45.77% 37.24%
Depreciation, Depletion And Amortization $6.064M $103.0K
YoY Change 0.15% -11.97%
Cash From Operating Activities $37.06M $42.56M
YoY Change 9.88% 47.51%
INVESTING ACTIVITIES
Capital Expenditures $205.0K $0.00
YoY Change -600.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities -$7.566M -$1.790M
YoY Change -66.23%
Cash From Investing Activities -$7.771M -$1.790M
YoY Change -65.38% -95.53%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $500.0K
YoY Change 0.0%
Cash From Financing Activities -339.0K 3.409M
YoY Change -145.2% 146.49%
NET CHANGE
Cash From Operating Activities 37.06M 42.56M
Cash From Investing Activities -7.771M -1.790M
Cash From Financing Activities -339.0K 3.409M
Net Change In Cash 28.95M 44.18M
YoY Change 140.59% -550.34%
FREE CASH FLOW
Cash From Operating Activities $37.06M $42.56M
Capital Expenditures $205.0K $0.00
Free Cash Flow $36.86M $42.56M
YoY Change 9.14% 47.74%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
3286000
CY2023Q1 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
1358000
CY2022Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
1135000
CY2023Q1 hrmy Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
1075000
CY2022Q4 hrmy Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
358000
CY2023Q1 hrmy Accrued Professional Fees Consulting And Other Services
AccruedProfessionalFeesConsultingAndOtherServices
708000
CY2022Q4 hrmy Accrued Professional Fees Consulting And Other Services
AccruedProfessionalFeesConsultingAndOtherServices
1163000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1845000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
773000
CY2022Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
4236000
CY2022Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.028
CY2022Q1 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.038
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.063
CY2022Q1 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.064
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.029
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.004
CY2022Q1 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.155
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.220
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.081
CY2022Q4 us-gaap Assets Current
AssetsCurrent
400285000
CY2022Q1 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2023Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2023Q1 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-39450
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
HARMONY BIOSCIENCES HOLDINGS, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
470000
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2279923
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
630 W.
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Germantown Pike
CY2023Q1 dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 215
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Plymouth Meeting
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19462
CY2023Q1 dei City Area Code
CityAreaCode
484
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
539-9800
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
573000
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.00001 value per share
CY2023Q1 dei Trading Symbol
TradingSymbol
HRMY
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
59954618
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
287962000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
243784000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4628000
CY2023Q1 us-gaap Short Term Investments
ShortTermInvestments
55916000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
79331000
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
52575000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
54740000
CY2023Q1 us-gaap Inventory Net
InventoryNet
4090000
CY2022Q4 us-gaap Inventory Net
InventoryNet
4297000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
5017000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
3829000
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
11399000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
9347000
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
6145000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
8786000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
418087000
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2023Q1 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001802665
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2022Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
59954618
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59615731
CY2022Q1 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2023Q1 us-gaap Long Term Investments
LongTermInvestments
48538000
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
22568000
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
154992000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
160953000
CY2023Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
89385000
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
85943000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2870000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2798000
CY2023Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
297005000
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
273585000
CY2023Q1 us-gaap Assets
Assets
715092000
CY2022Q4 us-gaap Assets
Assets
673870000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
6414000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3786000
CY2023Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
5691000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
11532000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
56810000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
59942000
CY2023Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
6500000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2000000
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
9948000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1624000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
85363000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
78884000
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
185063000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
189647000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1625000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2501000
CY2023Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
186688000
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
192148000
CY2023Q1 us-gaap Liabilities
Liabilities
272051000
CY2022Q4 us-gaap Liabilities
Liabilities
271032000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59954618
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
59615731
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
685716000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
675118000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-31000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-151000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-242645000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-272130000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
443041000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
402838000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
715092000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
673870000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
119126000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
85313000
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
20780000
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
14716000
CY2023Q1 us-gaap Gross Profit
GrossProfit
98346000
CY2022Q1 us-gaap Gross Profit
GrossProfit
70597000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13289000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7578000
CY2023Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
22572000
CY2022Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
17583000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22062000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17880000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
57923000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
43041000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
40423000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
27556000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-2645000
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-4169000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
37780000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
23385000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8295000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1900000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
29485000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
21485000
CY2023Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
120000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
29605000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
21485000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.49
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.36
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.48
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.35
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59732157
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58908526
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61221511
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60586875
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
402838000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
29485000
CY2023Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
120000
CY2023Q1 hrmy Stock Issued During Period Value Stock Options And Restricted Stock Units Exercised
StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercised
3395000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7203000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
443041000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
186507000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
21485000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1883000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
214503000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
29485000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
21485000
CY2023Q1 us-gaap Depreciation
Depreciation
103000
CY2022Q1 us-gaap Depreciation
Depreciation
117000
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5961000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5082000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
7203000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4628000
CY2023Q1 hrmy Stock Appreciation Rights Market Adjustment
StockAppreciationRightsMarketAdjustment
-642000
CY2022Q1 hrmy Stock Appreciation Rights Market Adjustment
StockAppreciationRightsMarketAdjustment
268000
CY2023Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
416000
CY2022Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
412000
CY2023Q1 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-3442000
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
636000
CY2023Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
369000
CY2022Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
385000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2165000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3290000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-207000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
165000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-592000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2235000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
2628000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
5903000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1850000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3586000
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-152000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
42559000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
28852000
CY2023Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
47776000
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
45986000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
45000
CY2022Q1 hrmy Cash Paid For Milestones
CashPaidForMilestones
40000000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1790000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-40045000
CY2023Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
500000
CY2022Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
500000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3909000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1883000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3409000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1383000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
44178000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9810000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
244534000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
235059000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
288712000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
225249000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-242645000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-272130000
CY2023Q1 us-gaap Investments And Cash
InvestmentsAndCash
392416000
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosures in the unaudited condensed consolidated financial statements, including the notes thereto, and elsewhere in this report. Actual results may differ significantly from estimates, which include rebates due pursuant to commercial and government contracts, accrued research and development expenses, stock-based compensation expense and income taxes. </p>
CY2023Q1 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
19060000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
287962000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
243784000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
288712000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
244534000
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Concentrations of Risk</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Substantially all of the Company’s cash and money market funds are held in two financial institutions. Due to their size, the Company believes these financial institutions represent minimal credit risk. Deposits may exceed the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation for U.S. institutions. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company believes that it is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is also subject to credit risk from its trade receivables related to its product sales. The Company extends credit to specialty pharmaceutical distribution companies within the United States. Customer creditworthiness is monitored and collateral is not required. Historically, the Company has not experienced credit losses on its accounts receivable. The Company monitors its exposure within accounts receivable and would record a reserve against uncollectible accounts receivable if necessary As of March 31, 2023, three customers accounted for 100% of gross accounts receivable; Accredo Health Group, Inc. (“Accredo”), which accounted for 41% of gross accounts receivable; Caremark LLC (“CVS Caremark”), which accounted for 30% of gross accounts receivable; and PANTHERx Specialty Pharmacy LLC (“Pantherx”), which accounted for 29% of gross accounts receivable. As of December 31, 2022, three customers accounted for 100% of gross accounts receivable; CVS Caremark, which accounted for 41% of gross accounts receivable, Accredo, which accounted for 35% of gross accounts receivable; and Pantherx, which accounted for 24% of gross accounts receivable.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the three months ended March 31, 2023, three customers accounted for 100% of gross product revenues; CVS Caremark accounted for 35% of gross product revenues; Pantherx accounted for 33% of gross product revenues; and Accredo accounted for 32% of gross product revenues. For the three months ended March 31, 2022, three customers accounted for 100% of gross product revenues; CVS Caremark accounted for 38% of gross product revenues; Pantherx accounted for 32% of gross product revenues; and Accredo accounted for 30% of gross product revenues.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company depends on a single source supplier for each of its product and active pharmaceutical ingredient.</p>
CY2023Q1 hrmy Concentrations Of Risk Number Of Financial Institutions
ConcentrationsOfRiskNumberOfFinancialInstitutions
2
CY2023Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
289988000
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
286876000
CY2023Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
776000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
838000
CY2023Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
1690000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1513000
CY2023Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2243000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2565000
CY2023Q1 us-gaap Inventory Gross
InventoryGross
4709000
CY2022Q4 us-gaap Inventory Gross
InventoryGross
4916000
CY2023Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
619000
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
619000
CY2023Q1 us-gaap Inventory Net
InventoryNet
4090000
CY2022Q4 us-gaap Inventory Net
InventoryNet
4297000
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5961000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5082000
CY2022Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
25367000
CY2023Q1 hrmy Accrued Rebates And Other Sales Deductions Current
AccruedRebatesAndOtherSalesDeductionsCurrent
28933000
CY2022Q4 hrmy Accrued Rebates And Other Sales Deductions Current
AccruedRebatesAndOtherSalesDeductionsCurrent
27860000
CY2023Q1 us-gaap Interest Payable Current
InterestPayableCurrent
3831000
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
17884000
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
23845000
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
23845000
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
23845000
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
23845000
CY2023Q1 hrmy Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
41728000
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
154992000
CY2023Q1 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
215000000
CY2022Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
215000000
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
60008000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
54047000
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
154992000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
160953000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
56810000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
59942000
CY2023Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
197000000
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
197500000
CY2023Q1 hrmy Unamortized Debt Discount Associated With Exit Fee Debt Financing Costs And Discount With Warrant Financing
UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing
5437000
CY2022Q4 hrmy Unamortized Debt Discount Associated With Exit Fee Debt Financing Costs And Discount With Warrant Financing
UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing
5853000
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
191563000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
191647000
CY2023Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
6500000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2000000
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
185063000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
189647000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
1500000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
20000000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
20000000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
155500000
CY2023Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
197000000
CY2023Q1 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
5315000
CY2022Q1 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
3824000
CY2023Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
416000
CY2022Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
412000
CY2023Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
5731000
CY2018Q2 hrmy Operating Lease Office Space
OperatingLeaseOfficeSpace
15000
CY2018Q2 hrmy Operating Lease Additional Office Space Leased One
OperatingLeaseAdditionalOfficeSpaceLeasedOne
13000
CY2018Q2 hrmy Operating Lease Additional Office Space Leased Two
OperatingLeaseAdditionalOfficeSpaceLeasedTwo
7000
CY2023Q1 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2023Q1 us-gaap Lessee Operating Lease Existence Of Option To Terminate
LesseeOperatingLeaseExistenceOfOptionToTerminate
true
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
378000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
385000
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y6M
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.046
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2384000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2312000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1874000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1614000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
741000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
975000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
2615000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2589000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
428000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
434000
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
526000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
234000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1462000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1102000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
143000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
10000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2717000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
102000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
2615000
CY2023Q1 us-gaap Loss Contingency Pending Claims Number
LossContingencyPendingClaimsNumber
0
CY2023Q1 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one vote for each share
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6460947
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
30.90
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M9D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
99797
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
41.52
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
324301
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
12.06
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
158798
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
21.61
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6077645
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
32.32
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M7D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7632
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7257
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7708
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0355
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0363
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0199
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0405
CY2023Q1 hrmy Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Lack Of Marketability Discount
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount
0.0000
CY2022 hrmy Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Lack Of Marketability Discount
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount
0.0000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6561000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4896000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
77333000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M18D
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
29485000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
21485000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.49
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.36
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.48
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.35
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59732157
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58908526
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61221511
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60586875
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2023Q1 us-gaap Related Party Transaction Due From To Related Party
RelatedPartyTransactionDueFromToRelatedParty
0
CY2022Q4 us-gaap Related Party Transaction Due From To Related Party
RelatedPartyTransactionDueFromToRelatedParty
0

Files In Submission

Name View Source Status
0001558370-23-007571-index-headers.html Edgar Link pending
0001558370-23-007571-index.html Edgar Link pending
0001558370-23-007571.txt Edgar Link pending
0001558370-23-007571-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hrmy-20230331.xsd Edgar Link pending
hrmy-20230331x10q.htm Edgar Link pending
hrmy-20230331xex31d1.htm Edgar Link pending
hrmy-20230331xex31d2.htm Edgar Link pending
hrmy-20230331xex32d1.htm Edgar Link pending
hrmy-20230331xex32d2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
hrmy-20230331_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
hrmy-20230331_def.xml Edgar Link unprocessable
hrmy-20230331x10q_htm.xml Edgar Link completed
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
hrmy-20230331_lab.xml Edgar Link unprocessable
hrmy-20230331_pre.xml Edgar Link unprocessable